Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
13 hedge funds and large institutions have $2.52M invested in Genetic Technologies Ltd. in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
13% less funds holding
Funds holding: 15 → 13 (-2)
15% less capital invested
Capital invested by funds: $2.96M → $2.52M (-$439K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$180K |
| 2 |
Bank of New York Mellon
New York
|
+$39.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$12.6K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.16K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$3.83K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$570K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$324K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$53K |
| 4 |
AS
Arxis Securities
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $1M | +$180K | +7,915 | +23% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $761K | -$324K | -14,198 | -31% |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $678K | -$570K | -25,013 | -47% |
|
|
4
Bank of New York Mellon
New York
| $42K | +$39.6K | +1,736 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| $13K | +$12.6K | +553 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $10K | +$8.16K | +358 | +716% |
|
|
CG
7
Cutler Group
San Francisco,
California
| $5K | – | – | – |
|
|
8
Simplex Trading
Chicago,
Illinois
| $5K | +$3.83K | +168 | +350% |
|
|
LTFS
9
Ladenburg Thalmann Financial Services
Miami,
Florida
| $3K | – | – | – |
|
10
Morgan Stanley
New York
| $2K | – | – | – |
|
|
TSS
11
Two Sigma Securities
New York
| – | -$53K | -2,450 | Closed |
|
|
AS
12
Arxis Securities
New York
| – | -$12K | -594 | Closed |
|
GENE Hedge Fund Activity: Q1 2017 in Review
13 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q1 2017, worth a combined $2.52M — down 15% from $2.96M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GENE and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $180K. The largest seller was Sabby Management, cutting an estimated $570K.
- 13 institutional investors held Genetic Technologies Ltd. (GENE) as of Q1 2017, down from 15 in Q4 2016.
- Funds reported $2.52M of Genetic Technologies Ltd. stock for Q1 2017, down 15% quarter-over-quarter.
- 2 funds opened new Genetic Technologies Ltd. positions in Q1 2017 and 4 closed out, a net change of -2 holders.
- The largest Genetic Technologies Ltd. buyer in Q1 2017 was Renaissance Technologies, an estimated $180K added.
- The largest Genetic Technologies Ltd. seller in Q1 2017 was Sabby Management, an estimated $570K sold.
Based on aggregated 13F filings for Q1 2017.